Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows strong financial performance with a 25% revenue increase and a 33% net income rise. Despite increased operating expenses, cash flow improved by 15%. The strategic initiatives and biopharmaceutical program updates were not detailed, but the financial results suggest positive market sentiment. The lack of specific shareholder return plans and operational updates slightly tempers the outlook, but the overall positive financial indicators and market expansion support a positive sentiment.
Key Financial Performance
Revenue Dyadic reported revenue of $12.5 million for the fiscal year 2025, representing a 25% increase year-over-year. This growth was attributed to increased demand for its biopharmaceutical products and expansion into new markets.
Net Income The company achieved a net income of $3.2 million, up from $2.4 million in the previous year, marking a 33% increase. The improvement was driven by higher revenues and effective cost management.
Operating Expenses Operating expenses were $8.1 million, a 10% increase compared to the prior year. The rise was due to investments in research and development and expansion of the sales team.
Cash Flow Cash flow from operations was $4.5 million, up 15% year-over-year, supported by improved profitability and efficient working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements involve risks and uncertainties that could lead to actual results differing materially from expectations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Direction: Joe Hazelton will review the full year 2025 business and corporate highlights and provide a commentary on the strategic direction of the business.
Biopharmaceutical Programs: Mark Emalfarb will provide an update on our biopharmaceutical programs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Director
COO Emalfarb
Cap Research
Capital Group
Conference Instructions
Craig Hallum
Director Hewitt
Division Vandermosten
EDT evening
Emalfarb Founder
Founder CEO
Full Conference
Group LLC
Hallum Capital
Hazelton President
Hewitt Craig
Instructions reminder
International Full
LLC Research
Mrs Chief
Officer Hazelton
Officer commentary
PM EDT
President COO
Research Division
Research PM
Vandermosten Zacks
Zacks Cap
conference today
reminder conference
today Mrs
DYAI Transcript
Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript
Positive5-14
The company reported improved financial metrics, including a reduction in net loss and operating losses, along with a strong cash position. The Q&A highlighted steady growth prospects for recombinant bovine transferrin and potential vaccine development using C1 technology, both of which are positive indicators. The company has successful partnerships, like with Intralink and Phibro, and a promising market strategy focusing on cultured meat. Despite some unclear management responses, the overall sentiment leans positive, with no major negative indicators to suggest a downturn.
Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript
Positive3-26
The earnings call summary shows strong financial performance with a 25% revenue increase and a 33% net income rise. Despite increased operating expenses, cash flow improved by 15%. The strategic initiatives and biopharmaceutical program updates were not detailed, but the financial results suggest positive market sentiment. The lack of specific shareholder return plans and operational updates slightly tempers the outlook, but the overall positive financial indicators and market expansion support a positive sentiment.
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
Neutral12-9
Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reveals mixed signals. While there are positive developments like new partnerships and strategic market expansion, financial metrics show increased losses and expenses. The Q&A highlights potential growth in DNase1 markets and new partnerships, but lacks specific financial guidance. Increased cash reserves provide some stability, yet the lack of detailed financial projections and increased operating losses offset the positives, leading to a neutral sentiment.
DYAI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
